Eli Lilly is moving to acquire Kelonia Therapeutics in a multi billion dollar deal to strengthen its oncology pipeline, particularly in next generation CAR-T cell therapies.
Glimpse:
Announced in April 2026, Eli Lilly entered advanced discussions to acquire Kelonia Therapeutics for over $2 billion, with later confirmations indicating the deal could reach up to $7 billion including milestone payments. The acquisition focuses on Kelonia’s in vivo CAR-T technology, which aims to simplify cancer treatment by engineering immune cells directly inside the body.
Eli Lilly has taken a major step to expand its oncology portfolio by moving to acquire Boston based biotech firm Kelonia Therapeutics. Initial reports suggested a deal valued at over $2 billion, but subsequent confirmations indicate the total transaction value could reach up to $7 billion, including milestone based payouts.
Kelonia Therapeutics specializes in in vivo CAR-T therapies, an emerging approach in cancer treatment that modifies a patient’s immune cells directly inside the body eliminating the need for complex external cell engineering and chemotherapy processes used in traditional CAR-T therapies.
Its lead candidate, KLN-1010, is currently in early stage clinical trials targeting multiple myeloma, a form of blood cancer. Early data has shown promising potential, positioning the therapy as a next-generation alternative in the rapidly evolving cell therapy landscape.
For Eli Lilly, the acquisition aligns with its broader strategy to diversify beyond its diabetes and obesity portfolio and strengthen its presence in oncology a market projected to grow significantly in the coming years.
The deal also reflects Lilly’s aggressive M&A approach, as the company continues to invest in innovative biotech platforms, including gene therapies and next-generation cell therapies, to remain competitive with global pharmaceutical leaders.
Industry experts highlight that in vivo CAR-T is considered a potential “holy grail” in cancer treatment due to its scalability, reduced cost, and ability to improve patient access compared to conventional therapies.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and standard closing conditions.
“In vivo CAR-T is viewed as the ‘holy grail’ of cell therapy.”
By
HB Team
Related News
